Keeping Up To Date on the Explosion of Cancer Immunotherapy
Flashcards
Flashcards

Keeping Up To Date on the Explosion of Cancer Immunotherapy

Not a member of My prIME? Join now for instant access.

This activity features interactive flashcards covering key topics from Keeping Up to Date With the Explosion of Immunotherapy in Cancer, our satellite symposium in collaboration with the Society for Immunotherapy of Cancer (SITC).

CME

CME

0.25 AMA PRA Category 1 Credit

Release Date

Release Date

Jul 18, 2017

Expiration Date

Jun 18, 2018

This educational activity is specifically designed to meet the needs of practicing medical oncologists, surgical and radiation oncologists, pathologists, and other healthcare professionals involved in the treatment of patients with cancer.

After successful completion of this educational activity, participants should be able to:

  • Identify patterns of response and specific adverse events associated with immunotherapies
  • Evaluate the evidence on the role of biomarkers for immunotherapies and their interpretation
  • Assess combination treatment strategies utilizing immunotherapy agents
  • Compare novel and emerging immunotherapies with established treatment options

This educational activity is supported by grants from Bristol-Myers Squibb and Merck & Co, Inc.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Keeping Up To Date on the Explosion of Cancer Immunotherapy - prIME Oncology

prIME Oncology designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Govindan has disclosed that he has received consulting fees from AbbVie, ARIAD, Astellas, AstraZeneca, Baxalta, Bristol-Myers Squibb, Genentech, INC, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Morse has disclosed that he has received consulting fees from EMD Serono. He has performed contracted research for Aduro, Alphavax, Bristol-Myers Squibb, Etubics, Newlinks, and Precision Biologics. He also received fees for non-CME services received directly from Celgene, Genentech, Novartis, Merrimack, and Taiho. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Nanda has disclosed that she has received consulting fees from Celgene, Peregrine, Pfizer, Puma, and Syndax. She performed contracted research for Celgene, Corcept Therapeutics, and Merck. She also received fees for non-CME services received directly from Genentech. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Rini has disclosed that he has received consulting fees from Pfizer and Merck. He also performed contracted research for or received research support from Bristol-Myers Squibb, Pfizer, and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Seiwert has disclosed that he has received consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Jounce Therapeutics, Merck, and Merck-Serono. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Soria has disclosed that he has received consulting fees from AstraZeneca, Astex, Covagen, Clovis, GlaxoSmithKline, Gammamabs, Lilly, MSD, Mission Therapeutics, Merus, Pfizer, Pierre Fabre, Roche-Genentech, Sanofi, Servier, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Sznol has disclosed that he has received consulting fees from or participated in advisory boards for Adaptimmune, Astra-Zeneca/Medimmune, Alexion, Agonox, Arbutus, Bristol-Myers Squibb, Baxalta-Shire, Genentech-Roche, Ignyta, Inovio, Lilly, Lion Biotechnologies, Lycera, Merck, Modulate, Nektar, Omniox, Pfizer, Pieris, Pierre Fabre, Seattle Genetics, Symphogen, and Theravance. He also received stock options for participation in advisory boards from Amphivena, Adapative Biotechnologies, and Intensity. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Bojana Pajk, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Elizabeth Cameron, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.